Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Autolus Therapeutics Q3 2026 Results: Net Loss of $55.1M, Loss Narrows

Autolus Therapeutics plc, a foreign private issuer voluntarily filing a Form 10-Q, reported 266,340,330 ordinary shares outstanding as of November 9, 2026. The filing highlights the commercialization of AUCATZYL for adult r/r B-ALL and notes a restructuring and workforce reduction plan initiated in April 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue41.221.2
Profit before tax-55.6-78.6
Net income-55.1-79.1
EPS (diluted, $ a share)$-0.21$-0.30

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+94.6%
Operating margin-105.6%
Source

10-Q filed with the SEC, NASDAQ: AUTL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Autolus Therapeutics plc: key numbers

Share price
$1.14Close, Nov 16
Market cap
$304M
Shares outstanding
266.34MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Autolus Therapeutics plc

All →
7:25 AM ET 8-K
Financial Results

Autolus Therapeutics Financial Results

Autolus Therapeutics reported Q3 2026 financial results, highlighted by $41.2 million in AUCATZYL net product revenue, a 95% year-over-year increase. The company raised its full-year 2026 revenue guidance for AUCATZYL to meet or exceed $150 million, driven by increased demand and manufacturing efficiencies that improved gross margins to 57%.

“We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain positive experience with the therapy, and supported by real-world data reported through the ROCCA consortium.”

Dr. Christian Itin, Chief Executive Officer

“AUCATZYL’s performance in adult r/r B-ALL is a key near-term value driver. Longer term, we believe expanding obe-cel across all stages of ALL and into autoimmune indications offers meaningful opportunities for scalable growth, leveraging its favorable profile and Autolus’ proven manufacturing and commercial capabilities.”

Dr. Christian Itin, Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.